argenx SE 2025 AR2
The report highlights argenx's strong operational and financial performance in 2025, with global product net sales of VYVGART reaching $4.2 billion. The company treated approximately 19,000 patients globally across three indications and successfully launched the VYVGART HYTRULO pre-filled syringe in the U.S., Europe, and Japan. Additionally, argenx advanced its pipeline with 10 ongoing registrational clinical trials and submitted a supplemental BLA for Seronegative gMG. The company also prepared for a leadership transition, with Karen Massey nominated to succeed Tim Van Hauwermeiren as CEO.
Company: argenx SE
Sector: Manufacturing
Country: Netherlands
Year: 2025
Type: AR2
Pages: 336
Back to company
argenx SE
Annual Report
The report highlights argenx's strong operational and financial performance in 2025, with global product net sales of VYVGART reaching $4.2 billion. The company treated approximately 19,000 patients globally across three indications and successfully launched the VYVGART HYTRULO pre-filled syringe in the U.S., Europe, and Japan. Additionally, argenx advanced its pipeline with 10 ongoing registrational clinical trials and submitted a supplemental BLA for Seronegative gMG. The company also prepared for a leadership transition, with Karen Massey nominated to succeed Tim Van Hauwermeiren as CEO.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Women on Board
Women in Management
Workplace Fatalities
Employees